Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Nov 1;6(6):pkac073.
doi: 10.1093/jncics/pkac073.

Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment

Elyse R Park  1   2   3   4 , Jordan M Neil  1   5   6 , Elise Noonan  1   2 , Sydney E Howard  7 , Irina Gonzalez  1   2 , Caylin Marotta  7 , Amy J Wint  7 , Douglas E Levy  2   3 , Yuchiao Chang  3   7 , Nancy A Rigotti  2   3   7 , Jennifer S Haas  2   7
Affiliations
Randomized Controlled Trial

Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment

Elyse R Park et al. JNCI Cancer Spectr. .

Abstract

The US Preventive Services Task Force recommends lung cancer screening (LCS) to promote early lung cancer detection, and tobacco cessation services are strongly recommended in adjunct. Screen ASSIST (NCT03611881) is a randomized factorial trial to ascertain the best tobacco treatment intervention for smokers undergoing LCS; trial outreach is conducted during 3 recruitment points (RPs): when LCS is ordered (RP1), at screening (RP2), and following results (RP3). Among 177 enrollees enrolled from April 2019 to March 2020, 31.6% enrolled at RP1, 13.0% at RP2, and 55.4% at RP3. The average number of enrollees (per 1000 recruitment days) was 2.26 in RP1, 3.37 in RP2, and 1.04 in RP3. LCS provides an opportunity to offer tobacco treatment at multiple clinical timepoints. Repeated and proactive outreach throughout the LCS experience was beneficial to enrolling patients in tobacco cessation services.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Recruitment flow and outreach efforts at each clinical recruitment timepoint including enrollment yield among smokers. Values within brackets are values at the 25th and 75th percentiles. LCS = lung cancer screening; RP1 = recruitment point before LCS; RP2 = recruitment point day of LCS to 7 days after; RP3 = recruitment point after LCS results received.
See this image and copyright information in PMC

References

    1. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
    1. Nguyen-Grozavu FT, Pierce JP, Sakuma KLK, et al. Widening disparities in cigarette smoking by race/ethnicity across education level in the United States. Prev Med. 2020;139:106220. doi: 10.1016/j.ypmed.2020.106220. - DOI - PMC - PubMed
    1. Zeliadt SB, Heffner JL, Sayre G, et al. Attitudes and perceptions about smoking cessation in the context of lung cancer screening. JAMA Intern Med. 2015;175(9):1530-1537. doi: 10.1001/jamainternmed.2015.3558 - DOI - PubMed
    1. Lennes IT, Luberto CM, Carr AL, et al. Project reach: piloting a risk-tailored smoking cessation intervention for lung screening. J Health Psychol. 2020;25(10-11):1472-1482. doi: 10.1177/1359105318756500 - DOI - PubMed
    1. Neil JM, Chang Y, Goshe B, et al. A web-based intervention to increase smokers’ intentions to participate in a cessation study offered at the point of lung screening: factorial randomized trial. JMIR Form Res. 2021;5(6):e28952. doi: 10.2196/28952. - DOI - PMC - PubMed

Publication types

Associated data